CLOs on the Move

INNOVA HEALTH SOLUTIONS

www.innovahealthsolutions.net

 
INNOVA HEALTH SOLUTIONS is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

MetaOptima Technology

MetaOptima: empowering users with advanced technologies MetaOptima is a digital health tech company dedicated to revolutionizing the dermatology and skin care industry with affordable, effective and intelligent tools. In order to provide state-of-the-art care, both medical professionals and their patients should be equipped with advanced tools. We are proud to offer two products designed to enhance the quality of patient care and organization while streamlining services for maximum efficiency: DermEngine and MoleScope. DermEngine is an intelligent skin analytics platform designed to provide medical experts with smart technologies to enhance workflows, organization and communications. MoleScope is a digital dermoscopic attachment for smartphones/tablets that allows users to take medical grade quality images of their skin. Here at MetaOptima, we take pride in our bold vision to bring digital healthcare and mobile technologies together to save lives and contribute to better health outcomes. We work hard to build a successful company with strong values and sense of community, as well as create jobs and develop tools that make the world a better place for patients, doctors, and businesses.

IntelliType Corporation

IntelliType Corporation is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ampio Pharmaceuticals

Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates.  These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending.  Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™.  The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.  Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema.  Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.

Avidon Health

Launched in 2020 following MedPro Wellness acquisition of SelfHelpWorks, Avidon Health is a team of behavior change experts who are passionate about providing health strategies that empower people to make positive life changes. We focus on the individual rather than the condition using innovative engagement technology, impactful courses and content, and care team support to drive meaningful outcomes at scale. Our mission: to change lives by fixing the engagement problem in healthcare.

MEDRAD Interventional/POSSIS

Possis Medical, Inc. is a developer, manufacturer and marketer of medical devices, operating in one business segment.